The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT

Thrombosis Research

Volumn 119, Issue 3, 2007, Pages 361-367

  Cimenti, Christina ^a   Koestenberger, Martin ^a   Leschnik, Bettina ^a   Haidl, Harald ^a   Muntean, Wolfgang ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Calibrated automated thrombography; Melagatran; rhAPC; Thrombin generation

Indexed keywords

ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DRUG COMBINATIONS; DRUG SYNERGISM; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS; THROMBIN TIME;

EID: 33845511129     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.03.004     Document Type: Article

References (29)

1. Bernard G.R., Vincent J.L., Laterre P.F., LaRosa S.P., Dhainaut J.F., Lopez-Rodriguez A., et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 (2001) 699-709
2. Espana F., Medina P., Navarro S., Zorio E., Estelles A., and Aznar. The multifunctional protein C system. Curr Med Chem Cardiovasc Hematol Agents 3 (2005) 119-131
3. Hoffman M., and Monroe III D.M. A cell-based model of hemostasis. Thromb Haemost 85 (2001) 958-965
4. Vincent J.L., Angus D.C., Artigas A., Kalil A., Basson B.R., Jamal H.H., et al. Recombinant human activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 31 (2003) 834-840
5. Laterre P.F., and Wittebole X. Clinical review: drotrecogin alfa (activated) as adjunctive therapy for severe sepsis-practical aspects at the bedside and patient identification. Crit Care 7 (2003) 445-450
6. Dhainaut J.F., Laterre P.F., Janes J.M., Bernard G.R., Artigas A., Bakker J., et al. Recombinant human activated Protein C Worldwide Evaluation in Sepsis (PROWESS) study group. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intense Care Med 29 (2003) 894-903
7. Johansson S., Wahlander K., Larson G., Ohlsson L., Larsson M., and Eriksson U.G. Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men. Blood Coagul Fibrinolysis 14 (2003) 677-684
8. Gulseth M.P. Ximelagatran: an orally active direct thrombin inhibitor. Am J Health-Syst Pharm 62 (2005) 1451-1467
9. Eriksson B.I., Bergqvist D., Kalebo P., Dahl O.E., Lindbratt S., Bylock A., et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 360 (2002) 1441-1447
10. Eriksson B. Clinical experience with ximelagatran in orthopaedic surgery. Drugs 64 (2004) S27-S35
11. Koestenberger M., Cvirn G., Gallistl S., and Muntean W. Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time. Blood Coagul Fibrinolysis 15 (2004) 693-697
12. Koestenberger M., Gallistl S., Muntean W., Leschnik B., Fritsch P., and Cvirn G. Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma. Thromb Haemost 94 (2005) 69-74
13. Koestenberger M., Gallistl S., Cvirn G., Baier K., Leschnik B., and Muntean W. Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination. Thromb Res 115 (2005) 135-142
14. Trzeciak S., and Dellinger R.P. Other supportive therapies in sepsis: an evidence-based review. Crit Care Med 32 Suppl 11 (2004) S 571-S 577
15. Hirsh J., and Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) S188-S203
16. Hemker H.C., Giesen P., Al Dieri R., Regnault V., de Smedt E., Wagenvoord R., et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33 (2003) 4-15
17. Butenas S., van't Veer C., and Mann K.G. "Normal" thrombin generation. Blood 94 (1999) 2169-2178
18. Mann K.G., Brummel K., and Butenas S. What is all that thrombin for?. J Thromb Haemost 1 (2003) 1504-1514
19. Cvirn G., Gallistl S., Koestenberger M., Baier K., Fritsch P., Greilberger J., et al. The anticoagulant action of recombinant human activated protein C (rhAPC, drotrecogin alpha activated): comparison between cord and adult plasma. Thromb Haemost 91 (2004) 912-918
20. Dempfle C.E. Coagulopathy of sepsis. Thromb Haemost 91 (2004) 213-224
21. Wahlander K., Lapidus L., Olsson C.G., Thuresson A., Eriksson U.G., Larson G., et al. Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb Res 107 (2002) 93-99
22. Gustafsson D., Nystrom J., Carlsson S., Bredberg U., Eriksson U., Gyzander E., et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 101 (2001) 171-181
23. Hemker H.C., Al Dieri R., and Beguin S. Thrombin generation assays: accruing clinical relevance. Curr Opin Hematol 11 (2004) 170-175
24. Hemker H.C., Giesen P., AlDieri R., Regnault V., de Smed E., Wagenvoord R., et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 32 (2002) 249-253
25. Al Dieri R., Alban S., Beguin S., and Hemker H.C. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost 2 (2004) 1395-1401
26. Bostrom S.L., Hansson G.F., Sarich T.C., and Wolzt M. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma. Thromb Res 113 (2004) 85-91
27. Regnault V., Hemker H.C., Wahl D., and Lecompte T. Phenotyping the haemostatic system by thrombography-potential for the estimation of thrombotic risk. Thromb Res 114 (2004) 539-545
28. Hemker H.C., and Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 74 (1995) 134-138
29. Van't Veer C., Golden N.J., Kalafatis M., and Mann K.G. Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. Synergistic effect in combination with tissue factor pathway inhibitor. J Biol Chem 272 (1997) 7983-7994